Pharming Group Report on Preliminary Financial Results for 2016
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the full year ended 31 December 2016.
Prospectus 2016
Financial updatesProspectus 2016 is available for download.
Pharming Launches Rights Issue to raise €12.1 million as part of RUCONEST® North American Rights Acquisition Financing
Financial updatesPharming Group N.V. announces the launch of a 1 for 7 Rights Issue of up to 58,943,624 shares to raise approximately €12.1 million to existing shareholders its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016 (the “Transaction”).
Pharming Announces Financing Plans for Closing of RUCONEST® North American Rights Acquisition
Financial updatesPharming Group N.V. announces its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016.